You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

PAM50

Showing 1 - 25 of 235
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Menstrual Cycle, PAM50, Ki67 on Treatment Decisions in HR+ and

Recruiting
  • Hormone Receptor Positive HER-2 Negative Breast Cancer
    • Tuebingen, Germany
      Department of Women's Health
    Jun 1, 2023

    Metastatic Breast Cancer Trial in Spain (Pembrolizumab, Paclitaxel)

    Active, not recruiting
    • Metastatic Breast Cancer
    • Hospitalet de Llobregat, Barcelona, Spain
    • +6 more
    Jan 23, 2023

    Neoadjuvant Operable Breast Cancer Trial in Paris, Villejuif (Fluorouracile, Epirubicin, Cyclophosphamide)

    Completed
    • Neoadjuvant Operable Breast Cancer
    • Paris, France
    • +1 more
    Mar 14, 2022

    Prosigna Assay on Neoadjuvant Clinical Decision-making in

    Recruiting
    • Breast Cancer
    • Prosigna PAM-50 assay
    • Boston, Massachusetts
      Dana-Farber Cancer Institute
    Apr 5, 2022

    Breast Cancer, Cancer of the Breast Trial in Saint Louis (VENTANA MIB-1 Ki67 assay, Oncotype DX® Recurrence Score, PAM50-based

    Not yet recruiting
    • Breast Cancer
    • Cancer of the Breast
    • VENTANA MIB-1 Ki67 assay
    • +4 more
    • Saint Louis, Missouri
      Washington University School of Medicine
    Apr 18, 2023

    HER2 Enriched Subtype Breast Cancer, Herzuma, PAM50 Study Trial (Herzuma)

    Not yet recruiting
    • HER2 Enriched Subtype Breast Cancer, Herzuma, PAM50 Study
    • (no location specified)
    Apr 25, 2021

    Breast Cancer Radiation Trial in United States (Prosigna)

    Active, not recruiting
    • Breast Cancer Radiation
    • Prosigna
    • Baltimore, Maryland
    • +5 more
    Jul 7, 2022

    East Asian Breast Cancer Genome Atlas and Recurrence Risk

    Recruiting
    • Breast Cancer
    • PAM50
    • Taipei, Taiwan
      National Taiwan University Hospital
    May 6, 2021

    Breast Cancer Trial in Spain (Atezolizumab + Trastuzumab + Vinorelbine)

    Recruiting
    • Breast Cancer
    • Atezolizumab + Trastuzumab + Vinorelbine
    • Granada, Andalucía, Spain
    • +14 more
    Mar 2, 2022

    Premenopausal Breast Cancer, Metastatic Breast Cancer, ER Positive Breast Cancer Trial in Taipei City (Goserelin, Fulvestrant,

    Recruiting
    • Premenopausal Breast Cancer
    • +2 more
    • Taipei City, Taiwan
      Department of Oncology, National Taiwan University Hospital
    Feb 7, 2023

    Breast Cancer, Hormone Receptor Positive Breast Carcinoma Trial in Badalona, Sant Cugat Del Vallès, Barcelona (Elacestrant)

    Completed
    • Breast Cancer
    • Hormone Receptor Positive Breast Carcinoma
    • Badalona, Barcelona, Spain
    • +3 more
    Oct 25, 2022

    Breast Cancer Trial in Barcelona, Lleida, Tarragona (Onapristone)

    Completed
    • Breast Cancer
    • Barcelona, Spain
    • +3 more
    Mar 31, 2022

    Breast Cancer, HER2-negative Breast Cancer, Hormone Receptor Positive Tumor Trial (Elacestrant, Triptorelin)

    Not yet recruiting
    • Breast Cancer
    • +3 more
    • (no location specified)
    Aug 4, 2023

    Older Women With ER Positive, HER2 Negative Early Breast Cancer

    Enrolling by invitation
    • Breast Cancer Female
    • Translational study
    • Sutton, United Kingdom
      The Royal Marsden NHS Foundation Trust
    Feb 8, 2023

    Metastatic Breast Cancer Trial in Spain (Palbociclib, Trastuzumab, Endocrine therapy)

    Recruiting
    • Metastatic Breast Cancer
    • Badalona, Barcelona, Spain
    • +34 more
    Oct 24, 2022

    Breast Cancer Trial in Sweden (Trastuzumab deruxtecan, Docetaxel, Paclitaxel)

    Not yet recruiting
    • Breast Cancer
    • Trastuzumab deruxtecan
    • +9 more
    • Malmö, Sweden
    • +6 more
    Jun 8, 2023

    Breast Cancer Trial in France (PAM 50 test)

    Terminated
    • Breast Cancer
    • PAM 50 test
    • Besançon, France
    • +15 more
    Jul 24, 2019

    Health Technology Intervention on Patient Activation in Multiple

    Not yet recruiting
    • Multiple Myeloma in Relapse
    • +3 more
      • (no location specified)
      Jan 9, 2023

      Arthritis, Rheumatoid Trial in Worldwide (, PH-797804)

      Completed
      Has Results
      • Arthritis, Rheumatoid
      • Malvern East, Victoria, Australia
      • +47 more
      Jul 26, 2021

      Breast Cancer Stage II Trial in France, Portugal, Spain (Ribociclib (neoadjuvant), Chemotherapy (adjuvant), Ribociclib

      Recruiting
      • Breast Cancer Stage II
      • Ribociclib (neoadjuvant)
      • +2 more
      • Avignon, France
      • +49 more
      Jul 7, 2022

      Breast Cancer Trial in Spain (U3 1402)

      Recruiting
      • Breast Cancer
      • U3 1402
      • Badalona, Barcelona, Spain
      • +9 more
      Apr 1, 2022

      Breast Cancer, Advanced Breast Cancer Trial in Shanghai (Everolimus 10 mg, CDK4/6 Inhibitor SHR6390, Aromatase inhibitor and

      Not yet recruiting
      • Breast Cancer
      • Advanced Breast Cancer
      • Everolimus 10 mg
      • +2 more
      • Shanghai, Shanghai, China
        Fudan University Shanghai Cancer Center
      Jul 14, 2023

      Innate on the Inflammatory Response to Endotoxin

      Recruiting
      • Asthma
      • +4 more
        • Research Triangle Park, North Carolina
          NIEHS Clinical Research Unit (CRU)
        Dec 7, 2022

        Triple Negative Breast Cancer, Locally Advanced Breast Cancer, Recurrent Breast Cancer Trial in London (Palbociclib, Avelumab)

        Recruiting
        • Triple Negative Breast Cancer
        • +5 more
        • Manchester, Greater Manchester, United Kingdom
        • +6 more
        Jan 5, 2023

        HER2-positive Breast Cancer, ER-Negative Breast Cancer, PR-Negative Breast Cancer Trial in Belgium, France (Pertuzumab and

        Recruiting
        • HER2-positive Breast Cancer
        • +3 more
        • Pertuzumab and tratuzumab fixed dose combination
        • Trastuzumab emtansine
        • Auchenflower, Australia
        • +84 more
        Jan 16, 2023